ArticleBMC geriatrics2025
The prevalence and burden of chronic kidney disease, patterns of anticoagulation prescribing, and major bleeding risk in older adults with atrial fibrillation.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIn older adults with atrial fibrillation (AF), the presence of comorbid chronic kidney disease (CKD) may be more challenging for optimal disease management, influence stroke prophylaxis with oral anticoagulation, and impact bleeding risk. We examined the prevalence and burden of CKD in older patients with AF, patterns of anticoagulation prescribing according to CKD stage, and major bleeding events.
methodsPatients aged 65 years and older with AF were enrolled in a cohort study from clinics in Massachusetts and Georgia between 2016 and 2018. Kidney function was assessed with estimated glomerular filtration rate (GFR) values at study enrollment. Anticoagulation therapy with direct acting oral anticoagulation therapy (DOAC) or warfarin; and major bleeding events were ascertained from medical records. Cox proportional hazards model was used to estimate the multivariable adjusted risk of two-year major bleeding events.
resultsParticipants' (n = 1,244) mean age was 75 years; 48% were women, and 86% were White. Overall, 25% had a normal GFR, 44%, 28%, and 3% had mild, moderate, and severe CKD/kidney failure, respectively. Patients with severe CKD/kidney failure were more likely to be the oldest participants, dependent in their instrumental activities of daily living, and had the highest burden of frailty, multimorbidity, and polypharmacy. Approximately 44% of patients with normal GFR and 39% of those with mild CKD were prescribed a DOAC, while a majority of those with severe CKD/kidney failure (69%) were prescribed warfarin. Overall, 8% (n = 105) experienced a major bleeding event over the 2-year follow-up. After adjusting for sociodemographic, psychosocial, geriatric, and clinical variables, patients with severe CKD/kidney failure (HR: 2.81 [95% CI:1.10-7.17]) had a higher bleeding risk than those with a normal GFR.
conclusionsIn managing older patients with AF and comorbid CKD, healthcare providers should be increasingly aware of the increased burden of frailty, dependence for care, multimorbidity, polypharmacy, and the high risk of major bleeding especially among those with severely impaired kidney function. This finding emphasizes the need for a more holistic and multidisciplinary approach to stroke prophylaxis in older adults with AF and comorbid CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.